CA2258840A1 - Induction of ctls specific for natural antigens by cross-priming immunization - Google Patents

Induction of ctls specific for natural antigens by cross-priming immunization Download PDF

Info

Publication number
CA2258840A1
CA2258840A1 CA002258840A CA2258840A CA2258840A1 CA 2258840 A1 CA2258840 A1 CA 2258840A1 CA 002258840 A CA002258840 A CA 002258840A CA 2258840 A CA2258840 A CA 2258840A CA 2258840 A1 CA2258840 A1 CA 2258840A1
Authority
CA
Canada
Prior art keywords
tumor
target antigen
artificial target
antigen
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002258840A
Other languages
English (en)
French (fr)
Inventor
Louis D. Falo, Jr.
Kenneth L. Rock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
University of Pittsburgh
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2258840A1 publication Critical patent/CA2258840A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA002258840A 1996-06-28 1997-06-18 Induction of ctls specific for natural antigens by cross-priming immunization Abandoned CA2258840A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/675,332 US5951975A (en) 1996-06-28 1996-06-28 Induction of CTLs specific for natural antigens by cross priming immunization
US08/675,332 1996-06-28

Publications (1)

Publication Number Publication Date
CA2258840A1 true CA2258840A1 (en) 1998-01-08

Family

ID=24710012

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002258840A Abandoned CA2258840A1 (en) 1996-06-28 1997-06-18 Induction of ctls specific for natural antigens by cross-priming immunization

Country Status (7)

Country Link
US (1) US5951975A (enExample)
EP (1) EP1007087A1 (enExample)
JP (1) JP2001524928A (enExample)
AU (1) AU724546B2 (enExample)
CA (1) CA2258840A1 (enExample)
IL (1) IL127661A (enExample)
WO (1) WO1998000163A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6994851B1 (en) * 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
CA2327835C (en) * 1998-04-08 2010-09-21 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
ATE384795T1 (de) * 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (en) * 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
EP1363938B1 (en) * 2000-08-03 2013-12-11 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
GB0026812D0 (en) * 2000-11-02 2000-12-20 Isis Innovation Cancer therapy
NZ530635A (en) * 2001-06-15 2007-03-30 Nordic Vaccine Technology As Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1409694A4 (en) * 2001-07-05 2006-02-08 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
SI1620456T1 (sl) * 2003-04-18 2014-05-30 Biotech Synergy, Inc. Hla-a2 s tumorjem povezan antigen peptidov in sestavki
EP1644048B1 (en) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
US7807187B2 (en) * 2003-05-13 2010-10-05 The University Of Massachusetts Endogenous adjuvant molecules and uses thereof
AU2005327198B2 (en) * 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
WO2006073970A2 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
WO2006081323A2 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
EP1856250B1 (en) * 2005-02-15 2013-07-24 The University of North Carolina At Chapel Hill New live virus vaccines
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US11559504B2 (en) * 2017-06-02 2023-01-24 The Penn State Research Foundation Ceramide nanoliposomes, compositions and methods of using for immunotherapy
EP4014988A4 (en) * 2019-08-13 2023-11-29 National Institutes of Biomedical Innovation, Health and Nutrition NOVEL TREATMENT AND PREVENTION OF A DISEASE BASED ON AN IMMUNOLOGICAL MEMORY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045320A (en) * 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP1025856A3 (en) * 1994-03-08 2002-10-16 Dana-Farber Cancer Institute Methods for modulating T Cell unresponsiveness

Also Published As

Publication number Publication date
IL127661A (en) 2001-11-25
US5951975A (en) 1999-09-14
EP1007087A1 (en) 2000-06-14
JP2001524928A (ja) 2001-12-04
AU3390097A (en) 1998-01-21
IL127661A0 (en) 1999-10-28
AU724546B2 (en) 2000-09-28
WO1998000163A1 (en) 1998-01-08

Similar Documents

Publication Publication Date Title
AU724546B2 (en) Induction of CTLs specific for natural antigens by cross-priming immunization
WO1998000163A9 (en) INDUCTION OF CTLs SPECIFIC FOR NATURAL ANTIGENS BY CROSS-PRIMING IMMUNIZATION
Flamand et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
Falo Jr et al. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity
Mayordomo et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
JP5127224B2 (ja) 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
Haupt et al. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy
Cohen et al. CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens
WO2004089413A1 (en) Nucleotide and cellular vaccine composition
McCarthy et al. Review Anti-idiotype vaccines.
AU716497B2 (en) Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
EP1274853B1 (en) Materials and methods relating to immune responses to fusion proteins
US7348015B2 (en) Antigen modified cancer cell vaccines for cancer therapy
CN101072582B (zh) 作为癌症疫苗佐剂的α胸腺肽
EP1039926A1 (en) Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity
Nawrath et al. Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model
JP2005528899A (ja) 抗原提示細胞の生成方法
US7176186B1 (en) Stimulation of cell-mediated immune responses by targeted particulate genetic immunization
Yi Dendritic cell-based immunotherapy in multiple myeloma
JP2001501220A (ja) オンコジーン産物および外来ｍｈｃ分子を用いる癌治療
US20040110283A1 (en) Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products
Jang et al. Simultaneous expression of allogenic class II MHC and B7. 1 (CD80) molecules in A20 B-lymphoma cell line enhances tumor immunogenicity
Ruffini et al. Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma
Benvenuti et al. Genetic vaccination for the immunotherapy of B-cell malignancies
Stevenson et al. DNA vaccination against cancer antigens

Legal Events

Date Code Title Description
FZDE Discontinued